华泰联合证券有限责任公司 关于爱尔眼科医院集团股份有限公司 2023 年半年度跟踪报告 | 保荐人名称：华泰联合证券有限责任公司 | 被保荐公司简称：爱尔眼科 | | --- | --- | | 保荐代表人姓名：丁明明 | 联系电话：010-56839300 | | 保荐代表人姓名：高元 | 联系电话：025-83387686 | 一、保荐工作概述 三、公司及股东承诺事项履行情况 | 公司及股东承诺事项 | 是否履 | 未履行承诺的原因及解决措施 | | --- | --- | --- | | | 行承诺 | | | 1．爱尔医疗投资集团有限公司、实际控制人陈 邦关于保证上市公司独立性的承诺 | 是 | 不适用 | | 2．爱尔医疗投资集团有限公司、实际控制人陈 | 是 | 不适用 | 2 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 不适用 | | 2．督导公司建立健全并有效执行规章制度的情况 | 是 | | （1）是否督导公司建立健全规章制度（包括 | | | ...

证券代码:300015 证券简称: 爱尔眼科 公告编号:2023-065 公司董事会将对控股股东爱尔投资上述承诺事项的履行情况持续进行监 督，并按相关法律法规及时履行信息披露义务。 一、承诺主体及持股情况 截至本公告日，爱尔投资持有公司股票 3,202,323,587 股，占公司总股本的 34.33%，其中无限售条件流通股 3,202,323,587 股，占公司总股本的 34.33%。 二、承诺函具体内容 1、自本承诺之日起 6 个月内（2023 年 8 月 23 日至 2024 年 2 月 22 日）， 爱尔投资不以任何方式减持持有的公司股份。 2、在上述承诺期间内，因公司送红股、公积金转增股本、配股等原因而 增加的股份，亦遵守前述不减持承诺。 3、爱尔投资将忠实履行承诺，如违反上述承诺，将依法承担相应法律责 任。 爱尔眼科医院集团股份有限公司 关于控股股东承诺不减持公司股份的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）于 2023 年 8 月 23 日收到公司控股股东爱尔医疗投资集团有限公司（以下简 ...

证券代码：300015 证券简称：爱尔眼科 爱尔眼科医院集团股份有限公司投资者关系活动记录表 编号：2023-006 投资者关系 √特定对象调研 □分析师会议 活动类别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名 西部证券：陆伏崴； 称及人员姓 汇添富基金：钱伟志 名 时间 2023 年 7 月 19 日 地点 公司会议室 上市公司接 董秘：吴士君 待人员姓名 董事会办公室工作人员 1、公司近期经营情况如何？ 答：公司经营正常。随着暑假旺季的来临，自六月底到七月初 出现了需求小高峰，三季度开局良好。二季度除五月份受"二阳" 影响患者就医外，整体情况稳中向好，各项战略目标稳步推进， 投资者关系 具体情况将在公司 2022 年半年报中披露，敬请关注。 活动主要内 容介绍 2、宏观经济对公司有何影响？ 答：对很多行业来说，近期有关部门发言人称宏观经济的数据 和微观的体感还是存在一定"温差"。在眼科医疗领域，没有观 察到明显的降级现象，反而是高端服务占比在持续提升。 宏观经济影响居民消费能力，进而对很多行业产生影响，对医 疗行业影响相对较小。一方面， ...

证券代码：300015 证券简称：爱尔眼科 爱尔眼科医院集团股份有限公司投资者关系活动记录表 编号：2023-005 投资者关系 √特定对象调研 □分析师会议 活动类别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名 中信证券：陈竹、宋硕； 称及人员姓 阿布扎比投资局：卢舍之 名 时间 2023 年 6 月 26 日 地点 公司会议室 上市公司接 董事长：陈邦 待人员姓名 董秘：吴士君 董事会办公室工作人员 1、请问公司的高端手术术式占比有什么样的变化？ 答：近几年公司的高端手术占比稳步上升，由以下原因共同促 成： 第一，公司领先的门诊量和手术量为医疗能力提升创造了良好 投资者关系 条件。如 ICL 手术，公司是手术量最大的机构。丰富的临床经验 活动主要内 不断提升技术水平，良好的口碑又吸引更多的患者，形成了正向 容介绍 循环。 第二，公司的诊疗技术一直保持和国际前沿同步。公司不断引 入先进的技术，经过严格的培训和带教后逐步推广，为整体高质 量提供可靠保障。 第三，公司对医疗治疗和标准要求极高，多项指标均达到三甲 或以上水平，对患者进行个性化实现 ...

证券代码：300015 证券简称：爱尔眼科 编号：2023-004 投资者关系 √特定对象调研 □分析师会议 活动类别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名 嘉实基金：姚志鹏、郝淼、汤舒婷、杨欢、程佳、邓云龙； 称及人员姓 国金证券：袁维； 名 UBS：陈晨，叶文嘉，刘嘉洲； Allianz：蒋磊； 方瀛研究与投资：邓乃天； 凯雷投资：谢四维； SuMi Trust：Sandy Shao； 方圆基金：赖少萍。 时间 2023 年 6 月 15-16 日 地点 公司会议室 上市公司接 董事长：陈邦 待人员姓名 董秘：吴士君 董事会办公室工作人员 1、公司未来如何保持增长的持续性？ 投资者关系 答：未来爱尔眼科毫无疑问还是会以医疗服务为主题，深耕眼 活动主要内 科行业。主要将从三个方面入手： 容介绍 首先，公司将进一步加强核心竞争力，夯实临床服务建设，以 促进存量医院经营工作的稳定发展。一方面，随着"1+8+N"战 略的持续推进，我们期望未来能够将长沙爱尔眼科医院打造成世 爱尔眼科医院集团股份有限公司投资者关系活动记录表 | --- | | ...

Dividend and Share Distribution - The company plans to distribute a cash dividend of 1 RMB per 10 shares and a capital reserve increase of 3 shares for every 10 shares held[2]. - The total number of shares for the dividend distribution is 7,176,525,335 shares[2]. - The proposed cash dividend for 2022 is ¥1.00 per 10 shares, totaling ¥717,652,533.50, along with a capital reserve increase of 3 shares for every 10 shares held[170]. - The total number of shares for the capital increase is 2,152,957,600 shares, based on a total share capital of 7,176,525,335 shares[171]. - The company distributed a cash dividend of ¥648,731,132.65 for the 2021 fiscal year, with a dividend policy that aligns with company regulations[168]. Financial Performance - The company reported a total revenue of RMB 10.5 billion for the year 2022, representing a year-on-year growth of 15%[7]. - The net profit for 2022 was RMB 2.1 billion, reflecting a 20% increase from 2021[8]. - The company aims to achieve a revenue target of RMB 12 billion for 2023, representing a growth of approximately 14%[7]. - The total operating revenue for 2022 was ¥16,109,946,687.31, representing a year-on-year increase of 7.39% from ¥15,000,809,438.22 in 2021[56]. - The company achieved a net profit of ¥2,368,785,535.97 for the reporting period, with a distributable profit of ¥3,814,585,765.11 at year-end[170]. Market Expansion and Acquisitions - The company plans to expand its hospital network by opening 20 new facilities in 2023, targeting a 10% increase in market share[7]. - The company has completed the acquisition of a regional competitor, which is expected to enhance its service capabilities and patient reach[8]. - The company has expanded its network of subsidiaries across various regions, enhancing its market presence[6]. - The company is exploring partnerships with international healthcare providers to enhance service offerings and expand its global footprint[8]. - The company has completed several acquisitions, including Ganzhou Aier Eye Hospital with an investment of CNY 49,097,400, holding a 60.87% stake[88]. Research and Development - The report indicates ongoing research and development efforts for new products and technologies[3]. - The company is investing RMB 500 million in R&D for new ophthalmic technologies and treatments over the next three years[7]. - The company has filed a national patent for a small molecule compound with therapeutic value for dry age-related macular degeneration (AMD) and published one SCI paper[71]. - The company has developed a myopia prediction system and an intelligent diagnosis system, achieving software copyrights for 2 items[72]. - The company has established a digital ophthalmology research institute to foster innovation and collaboration in the field of eye health[42]. Operational Efficiency and Cost Management - The gross profit margin improved to 45%, up from 42% in 2021, indicating better cost management[8]. - Operational efficiency improvements led to a reduction in costs by 8%, enhancing overall profitability[10]. - The company reported a significant reduction in financial expenses by 93.75%, down to CNY 6.65 million, primarily due to foreign exchange gains and losses[69]. - The company has implemented a comprehensive medical quality management system, ensuring full coverage of performance evaluation and safety standards across provinces[120]. - The company emphasizes a "quality first" medical service philosophy, implementing strict quality control systems and enhancing staff training[125]. Governance and Compliance - The company has a comprehensive governance structure, ensuring transparency and accountability in its operations[4]. - The company emphasized the importance of corporate governance and compliance with relevant laws and regulations, enhancing its governance structure and internal control systems[135]. - The company has established a performance evaluation and incentive system linking management compensation to business performance[137]. - The company strictly adhered to information disclosure requirements, ensuring timely and accurate communication with investors[137]. - The company has no significant discrepancies between its governance practices and the regulations set by the China Securities Regulatory Commission[138]. Social Responsibility and Environmental Initiatives - The report highlights the company's commitment to environmental and social responsibility initiatives[5]. - The company engaged in various public welfare activities across 31 provinces in China, focusing on vision health and poverty alleviation[192]. - The company has implemented a comprehensive environmental monitoring and management system for its wastewater treatment processes[190]. - The company’s commitment to social responsibility includes initiatives for eye health and community support, particularly in rural areas[192]. - Huangshi Aier's wastewater treatment facility meets the national and local water pollutant discharge standards, with a COD concentration of 12 mg/L[190]. Employee and Talent Management - The company has made significant progress in talent acquisition, with a focus on attracting international and leading industry talents to strengthen its workforce[47]. - The company has implemented a comprehensive performance evaluation system for its senior management, linking remuneration to performance outcomes[153]. - The company has a total of 21,056 medical personnel among its employees, highlighting its focus on healthcare services[165]. - The company has established a multi-faceted incentive mechanism combining salary, bonuses, stock options, and restricted stock to align employee compensation with company performance[166]. - The company’s management team is composed of individuals with advanced degrees and professional qualifications, contributing to its competitive advantage[149]. Future Outlook and Strategic Goals - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 12% to 15%[9]. - The company aims to maintain a strong financial position while pursuing growth opportunities in the healthcare sector[3]. - The company plans to continue expanding its market presence and investing in new technologies and products[19]. - The company is focused on high-quality development as its core strategy moving forward[117]. - The company is pursuing an international strategy and global technological innovation to become a leading innovative eye health service group domestically and internationally[117].

Financial Performance - The company's revenue for Q1 2023 reached ¥5,020,539,960.94, representing a 20.44% increase compared to ¥4,168,634,167.01 in the same period last year[4] - Net profit attributable to shareholders was ¥781,064,898.92, up 27.92% from ¥610,600,966.52 year-on-year[4] - Basic earnings per share rose to ¥0.1101, a 25.11% increase from ¥0.0880 in the same period last year[4] - Total operating revenue for Q1 2023 reached CNY 5,020,539,960.94, an increase of 20.5% compared to CNY 4,168,634,167.01 in the same period last year[19] - Net profit attributable to shareholders for Q1 2023 was CNY 1,124,159,535.27, representing a growth of 23.5% year-on-year[19] - The total operating profit for Q1 2023 was approximately CNY 1.15 billion, an increase of 27% compared to CNY 908 million in the same period last year[20] - Net profit for Q1 2023 reached CNY 900.70 million, up 30% from CNY 692.94 million in Q1 2022[20] - The company’s total comprehensive income for Q1 2023 was CNY 915.04 million, up from CNY 663.82 million in Q1 2022[20] Cash Flow and Assets - The net cash flow from operating activities increased by 59.95% to ¥1,653,223,002.26, compared to ¥1,033,576,295.45 in the previous year[4] - Total assets at the end of the reporting period were ¥28,360,189,318.17, reflecting a 6.70% increase from ¥26,578,845,623.29 at the end of the previous year[4] - Cash and cash equivalents at the end of Q1 2023 were CNY 800,000,000.00, down from CNY 900,000,000.00 at the beginning of the year[16] - The total cash and cash equivalents as of March 31, 2023, amounted to CNY 6,562,740,730.97, an increase from CNY 6,004,225,654.40 at the beginning of the year[15] - Accounts receivable increased to CNY 1,784,708,155.11 from CNY 1,583,103,086.31, indicating a rise of 12.7%[16] - Non-current assets totaled CNY 18,068,852,122.86, up from CNY 16,921,630,950.39 at the beginning of the year, marking an increase of 6.8%[17] - The company reported a net increase in cash and cash equivalents of CNY 558.52 million, contrasting with a decrease of CNY 313.02 million in the same quarter last year[24] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 252,295[10] - The largest shareholder, Aier Medical Investment Group Co., Ltd., holds 34.32% of the shares, totaling 2,463,241,139 shares[10] - The company reported that the number of shares held by the top 10 shareholders includes 2,463,241,139 shares held by the controlling shareholder, Aier Medical Investment Group Co., Ltd.[11] - The company’s actual controller, Chen Bang, holds 79.99% of the shares in the controlling shareholder, Aier Investment[11] - The total number of restricted shares at the beginning of the period was 1,373,477,764, with 45,621 shares released during the period, resulting in an ending balance of 1,373,432,143 restricted shares[14] - There were no new restricted shares added during the reporting period[14] - The company has no shareholders participating in margin financing and securities lending activities among the top 10 shareholders[11] Research and Development - The company reported a 16.40% increase in R&D expenses, totaling ¥66,549,935.52, compared to ¥57,175,077.44 in the previous year[8] - The company reported R&D expenses of CNY 66,549,935.52 for Q1 2023, which is an increase of 16.5% compared to CNY 57,175,077.44 in Q1 2022[19] Future Outlook - The company’s cash flow from operating activities is expected to improve in the upcoming quarters due to increased patient volume and service offerings[15] - The company plans to expand its market presence through new hospital openings and partnerships in the healthcare sector[15] - The company is focusing on the development of new technologies and products to enhance service delivery and patient care[15] - The management provided guidance for the next quarter, anticipating a revenue growth of approximately 15% year-over-year[15] Financial Expenses and Liabilities - Investment income decreased by 83.62% to ¥3,399,520.17 from ¥20,751,408.33 year-on-year[9] - The company experienced a 104.48% increase in financial expenses, amounting to ¥49,079,913.74, primarily due to exchange rate fluctuations[8] - Total liabilities at the end of Q1 2023 were CNY 9,757,834,488.07, compared to CNY 8,963,376,254.16 at the start of the year, reflecting a growth of 8.8%[18] - The cash outflow from investing activities was CNY 1.19 billion, compared to CNY 935.06 million in the same period last year, indicating increased investment activity[23] - The company’s cash flow from financing activities showed a net outflow of CNY 215.26 million, an improvement from a net outflow of CNY 487.56 million in the previous year[23]

证券代码：300015 股票简称：爱尔眼科 公告编号：2023-034 爱尔眼科医院集团股份有限公司 关于举办2022年年度网上业绩说明会的通知 欢迎广大投资者积极参与本次网上说明会。 （问题征集专题页面二维码） 特此公告。 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）定于2023年5月9日（周 二）15:00-17:00在全景网举办2022年年度网上业绩说明会，本次业绩说明会将采用 网络远程的方式举行，投资者可登陆全景网"投资者关系互动平台" （http://ir.p5w.net）参与本次年度业绩说明会。 出席本次说明会的人员有：公司董事长陈邦先生；副董事长、总经理李力先生； 独立董事陈收先生；副总经理兼财务总监刘多元先生；董事、副总经理兼董事会秘 书吴士君先生。 为充分尊重投资者、提升交流的针对性，现就公司2022年度业绩说明会提前向 投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于2023年5月8日（周 一）17：00前访问http://ir.p5w.net/zj/，或扫描下方二维码，进入问题征集专 ...